Advocacy Campaigns
CCA works to advocate for the IBD community in a range of ways:
- Lobbying governments for funding
- Providing submissions about health policy
- Raising consumer needs to researchers and industry
- Awareness campaigns
Current advocacy campaigns
Help improve the quality of life for regional Australians living with chronic inflammatory conditions
Closed 2022
Review of the National Medicines Policy
Closed October 2021.
Have your say on PBS listings for IBD Medications
The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on IBD medications which are being considered for PBS listing. If you would like to provide feedback on simplified access to adalimumab (Humira®) for those under 18 years, another biosimilar version of adalimumab (Yuflyma®), a nutritional formula for those with short bowel syndrome (Neocate® Syneo), a new capsule form of budesonide (Budenofalk®), a new oral treatment Etrasimod (Velsipity®) for UC, new dosage praparations for ustekinumab Stelara®, biosimilar version of ustekinumab (Wezlana), new dosing and risk assessment for vedolizumab (Entyvio®), then send us an email about what difference it has made/would make to your life to [email protected]. We will then forward all comments consolidated to PBAC. The closing date for comments to CCA is 28 January 2024.
Drug Name, form(s), strength(s) and Sponsor, Submission type (Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | Drug Type and Use (What is the drug used to treat?) | Listing requested by Sponsor / Purpose of Submission (Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
ADALIMUMAB Injection 20 mg in 0.2 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled syringe Injection 40 mg in 0.4 mL pre-filled pen Injection 80 mg in 0.8 mL pre-filled syringe Injection 80 mg in 0.8 mL pre-filled pen Humira® ABBVIE PTY LTD (Change to existing listing) | Immune-mediated inflammatory disease | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of immune-mediated inflammatory disease in paediatric patients. |
ADALIMUMAB Injection 80 mg in 0.8 mL pre-filled pen Injection 80 mg in 0.8 mL pre-filled syringe Yuflyma® CELLTRION HEALTHCARE AUSTRALIA PTY LTD (New PBS listing) | Complex refractory fistulising Crohn disease Ulcerative colitis Crohn disease Chronic plaque psoriasis Hidradenitis suppurativa | To request General Schedule Authority Required (Written) listing of Yuflyma® 80 mg for initial and first continuing treatment, and Authority Required (STREAMLINED) listing for subsequent continuing treatment under the same conditions as its reference biologic Humira®. |
AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS Oral powder 400 g (Neocate Syneo) Neocate® Syneo NUTRICIA AUSTRALIA PTY LIMITED (Other matters) | Cows’ milk protein enteropathy Severe cows’ milk protein enteropathy with failure to thrive Combined intolerance to cows’ milk protein, soy protein and protein hydrolysate formulae Proven combined immunoglobulin E (IgE) mediated allergy to cows’ milk protein and soy protein Cows’ milk anaphylaxis Severe intestinal malabsorption including short bowel syndrome Eosinophilic oesophagitis | To request Neocate® Syneo with new formulation continue to be listed on the PBS under the existing conditions. |
BUDESONIDE Capsule (enteric) 3 mg Budenofalk® DR FALK PHARMA AUSTRALIA PTY LTD (New PBS listing) | Crohn disease (CD) | To request a General Schedule Authority Required (STREAMLINED) listing of a new form of budesonide for the treatment of mild to moderate CD. |
ETRASIMOD Tablet 2 mg Velsipity® PFIZER AUSTRALIA PTY LTD (New PBS listing) | Ulcerative colitis | To request a General Schedule Authority Required (Written) listing for the treatment of moderate to severe ulcerative colitis. |
USTEKINUMAB Injection 45 mg in 0.5 mL single use pre-filled syringe Injection 45 mg in 0.5 mL single use pre-filled pen Injection 90 mg in 1 mL single use pre-filled syringe Injection 90 mg in 1 mL single use pre-filled pen Stelara® JANSSEN-CILAG PTY LTD (New PBS listing) | Psoriatic arthritis (PsA) Crohn disease (CD) Chronic plaque psoriasis (CPP) Ulcerative colitis Fistulising Crohn disease | To request Authority Required (Written) listing of new forms, and amendments to the current restrictions for severe CD and severe CPP to align with a change in the quantity required for adult patients resulting from the new listings. |
USTEKINUMAB Injection 45 mg in 0.5 mL vial Injection 45 mg in 0.5 mL pre-filled syringe Injection 90 mg in 1 mL pre-filled syringe Injection 130 mg in 26 mL vial Wezlana AMGEN AUSTRALIA PTY LIMITED (New PBS listing) | Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis | To request General Schedule and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of ustekinumab biosimilar under the same conditions as its reference biologic. |
VEDOLIZUMAB Injection 108 mg in 0.68 mL single use pre-filled pen Powder for injection 300 mg Entyvio® TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. (Change to existing listing) | Crohn disease Ulcerative colitis | To request a change to the clinical criteria to allow an additional dose of vedolizumab 300 mg at Week 10 for the initial treatment of severe Crohn disease. The submission also requested the removal of the requirement to assess the risk of developing progressive multifocal leukoencephalopathy during this treatment from all PBS listings for vedolizumab. |
For information about the PBS meeting click here.